Table 3.
Number and Proportion of Patients with Stage IV Non-Small Cell Lung Cancer receiving Immunotherapy or Chemo-immunotherapy Endorsing at Least Moderate/Occasional Past Week Symptoms on the NCI-PRO-CTCAE™, Overall and by Performance Status and Age
| Overall Sample (N = 60) | ECOG Performance Status | Age | |||||
|---|---|---|---|---|---|---|---|
| Past Week Symptoms – NCI PRO-CTCAE™ | n (%) At Least Moderate/Occasional Symptom | PS 0/1 (n = 41) n (%) | PS 2/3 (n = 19) n (%) | p | Age < 70 (n = 45) n (%) | Age 70+ (n = 15) n (%) | p |
| Constipation severity | 13 (21.7) | 8 (19.5) | 5 (26.3) | .74 | 8 (17.8) | 5 (33.3) | .28 |
| Diarrhea frequency | 11 (18.3) | 5 (12.2) | 6 (31.6) | .09 | 9 (20.0) | 2 (13.3) | .71 |
| Bowel incontinence frequency | 2 (3.3) | 2 (4.9) | 0 (0) | 1.0 | 2 (4.4) | 0 (0) | 1.0 |
| Abdominal pain frequency | 7 (11.7) | 5 (12.2) | 2 (10.5) | 1.0 | 7 (15.6) | 0 (0) | .18 |
| Fatigue severity | 30 (50.0) | 20 (48.8) | 10 (52.6) | .78 | 24 (53.3) | 6 (40.0) | .37 |
| Pain frequency | 25 (41.7) | 12 (29.3) | 13 (68.4) | .004 | 19 (42.2) | 6 (40.0) | .88 |
| Cough severity | 15 (25.0) | 7 (17.1) | 8 (42.1) | .06 | 12 (26.7) | 3 (20.0) | .74 |
| Wheezing severity | 7 (11.7) | 5 (12.2) | 2 (10.5) | 1.0 | 7 (15.6) | 0 (0) | .18 |
| Shortness of breath severity | 14 (23.3) | 9 (22.0) | 5 (26.3) | .75 | 10 (22.2) | 4 (26.7) | .74 |
| Rash (yes/no) | 16 (26.7) | 12 (29.3) | 4 (21.1) | .50 | 13 (28.9) | 3 (20.0) | .74 |
| Dry skin severity | 12 (20.7) | 7 (18.0) | 5 (26.3) | .50 | 11 (25.0) | 1 (7.1) | .26 |
| Itchy skin severity | 13 (22.4) | 8 (20.5) | 5 (26.3) | .74 | 11 (25.6) | 2 (13.3) | .48 |
| Muscle ache frequency | 24 (40.0) | 18 (43.9) | 6 (31.6) | .36 | 20 (44.4) | 4 (26.7) | .22 |
| Joint pain frequency | 20 (33.3) | 11 (26.8) | 9 (47.4) | .12 | 16 (35.6) | 4 (26.7) | .53 |
| Decreased appetite severity | 14 (23.3) | 7 (17.1) | 7 (36.8) | .11 | 11 (24.4) | 3 (20.0) | 1.0 |
| Arm or leg swelling severity | 7 (11.7) | 5 (12.2) | 2 (10.5) | 1.0 | 7 (15.6) | 0 (0) | .18 |
| Nausea frequency | 10 (16.7) | 7 (17.1) | 3 (15.8) | 1.0 | 9 (20.0) | 1 (6.7) | .43 |
Note. NCI-PRO-CTCAE™ = National Cancer Institute Patient Reported Outcomes version of the Common Terminology Criteria for Adverse Events-. Statistical significance was tested with chi-square or Fisher’s exact tests.